--- title: "Capricor Therapeutics Stock Slides As Q4 Earnings Miss Estimates" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/279076841.md" description: "Capricor Therapeutics shares fell 5.69% to $31.52 after reporting a wider-than-expected Q4 loss of 62 cents per share, missing estimates of 54 cents. Revenue dropped to zero from $11.1 million a year earlier, while operating expenses rose to $29.2 million. Despite the earnings miss, the company highlighted progress in its lead candidate, deramiocel, with a biologics license application under FDA review and positive results from the Phase 3 HOPE-3 trial. Analysts maintain a bullish outlook, with price targets of $60 and $58 from HC Wainwright and Piper Sandler, respectively." datetime: "2026-03-13T17:27:01.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/279076841.md) - [en](https://longbridge.com/en/news/279076841.md) - [zh-HK](https://longbridge.com/zh-HK/news/279076841.md) --- > 支持的语言: [English](https://longbridge.com/en/news/279076841.md) | [繁體中文](https://longbridge.com/zh-HK/news/279076841.md) # Capricor Therapeutics Stock Slides As Q4 Earnings Miss Estimates **Capricor Therapeutics Inc** (NASDAQ:CAPR) shares are trading lower Friday afternoon after the biotech company reported a wider-than-expected fourth-quarter loss, even as it highlighted regulatory and clinical progress for its lead Duchenne muscular dystrophy candidate, deramiocel. Here’s what investors need to know. - Capricor Therapeutics stock is feeling bearish pressure. Why are CAPR shares down? ## Capricor Reports Wider-Than-Expected Q4 Loss Capricor posted a quarterly loss of 62 cents per share, missing the consensus estimate of a 54-cent loss and worsening from a 16-cent loss in the prior-year period. Investors appeared to focus on the earnings miss and the absence of quarterly revenue, which fell to zero from about $11.1 million a year earlier. Total operating expenses rose to roughly $29.2 million from $18.8 million, while fourth-quarter net loss widened to about $30.2 million from $7.1 million. ## Capricor Says Phase 3 HOPE-3 Trial Met Primary Endpoint Still, Capricor paired the weak earnings print with a bullish corporate update. The company said its biologics license application for deramiocel remains under FDA review, with a PDUFA target action date of Aug. 22. It also said the Phase 3 HOPE-3 trial met its primary endpoint and a key secondary cardiac endpoint, while newly presented late-breaking data showed reductions in myocardial fibrosis, improved left ventricular ejection fraction in patients with baseline cardiomyopathy, and about 83% slowing of disease progression on a functional eating task. Capricor ended 2025 with about $318.1 million in cash, cash equivalents and marketable securities and said that should fund operations through 2027. ## Analysts Reaffirm Bullish Outlook on Capricor Stock On the analyst front, HC Wainwright reiterated a Buy rating and maintained a $60 price target, while Piper Sandler reiterated Overweight and raised its price target to $58 from $45. ## Capricor Shares Show Strong Bullish Momentum Capricor Therapeutics shares have surged over the past year, climbing from a low of about $4.60 in late 2025 to a recent high near $33.57 as momentum strengthened in recent months. The stock now trades well above its 20-, 50- and 200-day moving averages, signaling strong bullish momentum. ## CAPR Shares Slide Friday Afternoon **CAPR Price Action:** Capricor Therapeutics shares were down 5.69% at $31.52 at the time of publication on Friday, according to Benzinga Pro data. _Image: Adobe Stock Images_ ### 相关股票 - [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-CN/quote/ARKG.US.md) - [VG Health (VHT.US)](https://longbridge.com/zh-CN/quote/VHT.US.md) - [Capricor Therap (CAPR.US)](https://longbridge.com/zh-CN/quote/CAPR.US.md) - [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-CN/quote/XLV.US.md) - [Direxion S&P Biotech Bull 3X (LABU.US)](https://longbridge.com/zh-CN/quote/LABU.US.md) - [iShares Global Healthcare (IXJ.US)](https://longbridge.com/zh-CN/quote/IXJ.US.md) - [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-CN/quote/FBT.US.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-CN/quote/PBE.US.md) - [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-CN/quote/XBI.US.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-CN/quote/BBH.US.md) - [iShares US Pharma (IHE.US)](https://longbridge.com/zh-CN/quote/IHE.US.md) - [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-CN/quote/SBIO.US.md) - [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-CN/quote/IBBQ.US.md) - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-CN/quote/IBB.US.md) - [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-CN/quote/BIB.US.md) ## 相关资讯与研究 - [Arcutis Reports New Positive Phase 2 Results For ZORYVE Cream In Infant Atopic Dermatitis](https://longbridge.com/zh-CN/news/280971278.md) - [InSilico Medicine Strikes Multi-Billion-Dollar AI Drug Discovery Deal With Eli Lilly](https://longbridge.com/zh-CN/news/280909399.md) - [Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA | CAPR Stock News](https://longbridge.com/zh-CN/news/278565215.md) - [Merck's Enlicitide Decanoate Shows Greater LDL-C Reduction Than Oral Non-Statins At 8 Weeks](https://longbridge.com/zh-CN/news/281051985.md) - [EXCLUSIVE: Penny Stock Scienture Reports Revenue Surge, Expanding Market Access In 2025](https://longbridge.com/zh-CN/news/281015927.md)